Background: Niemann-Pick type C (NP-C) disease exhibits marked heterogeneity in its phenotype. This can pose diagnostic dilemmas and even delayed recognition of this condition.
Objective: To highlight the phenotypic variations and distinctive pathological and biochemical findings in this disorder.
Design: Descriptive case studies.
Setting: Tertiary care children's hospital and clinic.
Population Studied: Three cases of NP-C disease where diagnosis was delayed.
Results: In each of the three cases the clinical presentation was varied, one as neonatal hepatitis, the second with megaloblastic anemia, chronic hepatitis and short stature, and the third with neonatal hepatitis and chronic respiratory failure. Definitive diagnosis was established in each case by demonstration of defective cholesterol esterification in skin fibroblasts.
Conclusions: In the clinical setting of neonatal hepatitis, hepatosplenomegaly and undiagnosed neurological symptoms, NP-C disease should be considered in the differential diagnosis. Electron microscopic examination of skin biopsy is an effective screening test, although the definitive diagnosis should be made by the cholesterol esterification assay and filipin staining.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851368 | PMC |
| http://dx.doi.org/10.1093/pch/3.5.329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
To be or not to be phosphorylated: understanding the role of Ebola virus nucleoprotein in the dynamic interplay with the transcriptional activator VP30 and the host phosphatase PP2A-B56.
Emerg Microbes Infect
December 2025
Institute of Virology, Philipps-Universität Marburg, Marburg, Germany.
Ebola virus (EBOV) transcription is essentially regulated via dynamic dephosphorylation of its viral transcription activator VP30 by the host phosphatase PP2A. The nucleoprotein NP has emerged as a third key player in the regulation of this process by recruiting both the regulatory subunit B56 of PP2A and its substrate VP30 to initiate VP30 dephosphorylation and hence viral transcription. Both binding sites are located in close proximity to each other in NP's C-terminal-disordered region.
View Article and Find Full Text PDFInstationary metabolic flux analysis reveals that NPC1 inhibition increases glycolysis and decreases mitochondrial metabolism in brain microvascular endothelial cells.
Neurobiol Dis
January 2025
Department of Bioengineering, University of Maryland, College Park, MD 20742, United States of America. Electronic address:
Niemann Pick Disease Type C (NP-C), a rare neurogenetic disease with no known cure, is caused by mutations in the cholesterol trafficking protein NPC1. Brain microvascular endothelial cells (BMEC) are thought to play a critical role in the pathogenesis of several neurodegenerative diseases; however, little is known about how these cells are altered in NP-C. In this study, we investigated how NPC1 inhibition perturbs BMEC metabolism in human induced pluripotent stem cell-derived BMEC (hiBMEC).
View Article and Find Full Text PDFComparative Transcriptomic Analyses of Peripheral Blood Mononuclear Cells of COVID-19 Patients without Pneumonia and with Severe Pneumonia in the First Year of Follow-Up.
Viruses
July 2024
Koc University Research Center for Translational Medicine (KUTTAM), School of Medicine, Koc University, Istanbul 34010, Türkiye.
The multisystemic effects of COVID-19 may continue for a longer time period following the acute phase, depending on the severity of the disease. However, long-term systemic transcriptomic changes associated with COVID-19 disease and the impact of disease severity are not fully understood. We aimed to investigate the impact of COVID-19 and its severity on transcriptomic alterations in peripheral blood mononuclear cells (PBMCs) following 1 year of the disease.
View Article and Find Full Text PDFBuilding Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next Outbreak.
Health Secur
September 2024
Lauren Wiesner, MD, is Chair, Department of Emergency Medicine; Aaron Resnick, MA, is Program Director, Biocontainment Unit; Bethany Little, BSN, RN, NHDP-BC, is Nursing Operations Director and Training and Education Coordinator, Biocontainment Unit; Glenn Wortmann, MD, is Section Director, Infectious Diseases; Craig DeAtley, PA-C, is Director, Institute for Public Health Emergency Readiness; and Shane B. Kappler, MD, MS, FACEP, is Medical Director, Biocontainment Unit; all at MedStar Washington Hospital Center, Washington, DC. Lauren Wiesner is also an Associate Professor of Emergency Medicine; Glenn Wortmann is also a Professor of Clinical Medicine (Infectious Diseases); and Shane B. Kappler is also an Assistant Professor of Emergency Medicine and Microbiology and Immunology; all at Georgetown University School of Medicine, Washington, DC. Jade Flinn, MSN, RN, CCRN, CNRN, is Director of Operations, Johns Hopkins Special Pathogens Center, and Brian T. Garibaldi, MD, MEHP, FACP, FRCP(E), was Director, Johns Hopkins Special Pathogens Center, and Director, Johns Hopkins Biocontainment Unit; all at The Johns Hopkins Hospital, Baltimore, MD. Brooke Brewer, RN, MS, CIC, is Program Manager, Infection Prevention; Natalie A. Schnell, BSN, RN, R-BC, CIC, is an Infection Prevention Nurse Educator; and David A. Wohl, MD, and William A. Fischer II, MD, are Co-Directors; all at the Special Pathogen Response Center, Region 4 Emerging Special Pathogen Treatment Center, University of North Carolina Hospitals, Chapel Hill, NC. William A. Fischer II is also Director of Emerging Pathogens, Institute for Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC. Sharon Vanairsdale Carrasco, DNP, APRN, ACNS-BC, NP-C, CEN, FAEN, FAAN, is an Associate Professor, Nell Hodgson Woodruff School of Nursing, Emory University, and Program Director, Region 4 Ebola and Other Special Pathogens Treatment Center, Emory University Hospital/Children's Healthcare of Atlanta; both in Atlanta, GA.
In response to the growing number of outbreaks of emerging infectious diseases, the US Administration for Strategic Preparedness and Response (ASPR) has embarked on a plan to improve and expand special pathogen patient care capabilities. To achieve this, ASPR is developing a coordinated network of Regional Emerging Special Pathogen Treatment Centers (RESPTCs) to serve as state-of-the-art facilities staffed by a highly trained workforce to care for and manage special pathogen patients across the lifespan. The RESPTC network represents the operational arm of a broader US National Special Pathogen System of care to prevent and prepare for the next infectious disease outbreak.
View Article and Find Full Text PDFHigh-Level Isolation: A Landscape Analysis of Global Capabilities and Opportunities to Advance the Field.
Health Secur
September 2024
Lauren M. Sauer, MSc, is Associate Director of Research, Global Center for Health Security, Director, Special Pathogens Research Network, and Associate Professor, Department of Environmental, Agricultural and Occupational Health, College of Public Health; all at the University of Nebraska Medical Center, Omaha, NE.
High-level isolation units (HLIUs) have been established by countries to provide safe and optimal medical care for patients with high-consequence infectious diseases. We aimed to identify global high-level isolation capabilities and determine gaps and priorities of global HLIUs, using a multiple method approach that included a systematic review of published and gray literature and a review of Joint External Evaluations and Global Health Security Index reports from 112 countries. A follow-up electronic survey was distributed to identified HLIUs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!